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Vanadate impedes adipogenesis 
in Mesenchymal stem cells Derived 
from Different Depots within Bone
Frans Alexander Jacobs, Hanél Sadie-Van Gijsen, Mari van de Vyver and  
William Frank Ferris*
Department of Medicine, Division of Endocrinology, Faculty of Medicine and Health Sciences, Stellenbosch University, 
Cape Town, Western Cape, South Africa
Glucocorticoid-induced osteoporosis (GIO) is associated with an increase in bone 
marrow adiposity, which skews the differentiation of mesenchymal stem cell (MSC) 
progenitors away from osteoblastogenesis and toward adipogenesis. We have 
previously found that vanadate, a non-specific protein tyrosine phosphatase inhib-
itor, prevents GIO in rats, but it was unclear whether vanadate directly influenced 
adipogenesis in bone-derived MSCs. For the present study, we investigated the 
effect of vanadate on adipogenesis in primary rat MSCs derived from bone marrow 
(bmMSCs) and from the proximal end of the femur (pfMSCs). By passage 3 after 
isolation, both cell populations expressed the MSC cell surface markers CD90 
and CD106, but not the hematopoietic marker CD45. However, although variable, 
expression of the fibroblast marker CD26 was higher in pfMSCs than in bmMSCs. 
Differentiation studies using osteogenic and adipogenic induction media (OM and 
AM, respectively) demonstrated that pfMSCs rapidly accumulated lipid droplets within 
1 week of exposure to AM, while bmMSCs isolated from the same femur only formed 
lipid droplets after 3 weeks of AM treatment. Conversely, pfMSCs exposed to OM 
produced mineralized extracellular matrix (ECM) after 3 weeks, compared to 1 week 
for OM-treated bmMSCs. Vanadate (10 μM) added to AM resulted in a significant 
reduction in AM-induced intracellular lipid accumulation and expression of adipogenic 
gene markers (PPARγ2, aP2, adipsin) in both pfMSCs and bmMSCs. Pharmacological 
concentrations of glucocorticoids (1 μM) alone did not induce lipid accumulation in 
either bmMSCs or pfMSCs, but resulted in significant cell death in pfMSCs. Our 
findings demonstrate the existence of at least two fundamentally different MSC depots 
within the femur and highlights the presence of MSCs capable of rapid adipogenesis 
within the proximal femur, an area prone to osteoporotic fractures. In addition, our 
results suggest that the increased bone marrow adiposity observed in GIO may not 
be solely due to direct effect of glucocorticoids on bone-derived MSCs, and that an 
increase in femur lipid content may also arise from increased adipogenesis in MSCs 
residing outside of the bone marrow niche.
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inTrODUcTiOn
Glucocorticoids (GCs) are widely used to treat a variety of 
inflammatory disorders, but chronic GC use can reduce bone 
mineral density (BMD) and lead to GC-induced osteoporosis 
(GIO) through an increase in bone resorption and a decrease in 
bone formation (1, 2). The GC-induced decrease in formation 
may arise from a reduction in the pool of mesenchymal stem 
cells (MSCs) available for osteoblastic differentiation, resulting 
in smaller numbers of mature bone-forming osteoblasts (1, 2).
Osteoblasts arise from multipotent MSCs, which can also 
differentiate into other cell-types, including adipocytes and 
chondrocytes (3, 4), with several lines of evidence indicating an 
inverse reciprocal relationship between osteoblast and adipocyte 
differentiation (5). Several mechanisms have been identified 
whereby GCs may reduce the number of osteoprogenitor cells 
in bone. In vitro studies have suggested that GCs may reduce the 
number of MSCs destined for osteoblastogenesis by shifting the 
differentiation potential of MSCs preferentially toward adipogen-
esis (6, 7), and this is in agreement with in vivo observations of 
GC-induced increases in marrow adiposity (8). In addition, we 
have previously documented the anti-proliferative effects of GCs 
in Naïve adipose-derived MSCs and in partially differentiated 
osteoblasts derived from these cells (9). Evidence from in  vivo 
studies in mice and in  vitro studies on osteoblast cell-lines 
indicate that GCs may also directly cause apoptosis in osteopro-
genitors, osteoblasts, and osteocytes (10, 11). Taken together, 
these findings indicate that GCs have many deleterious effects 
on MSCs and on cells committed to the osteoblastic lineage, and 
that the prevention of these effects may restore both the number 
of MSCs available for osteoblastic differentiation and the number 
of functional osteoblasts in bone.
Earlier work in animal models found that GIO could be 
prevented by the non-selective protein tyrosine phosphatase 
inhibitor sodium orthovanadate (12), although the mechanism 
was not described in detail. It was subsequently shown that 
vanadate inhibited apoptosis of cultured osteoblasts in  vitro 
and of osteocytes in vivo (10). Vanadate has also been shown to 
counteract the anti-proliferative effects of GCs on Naïve MSCs 
and pre-osteoblasts (9), and to inhibit adipocytic differentiation 
in the 3T3-L1 pre-adipocyte cell line (13). Vanadate is therefore 
an attractive candidate for the prevention of GIO by reversing or 
counteracting the effects of GCs on osteoblast precursors, pos-
sibly through a variety of mechanisms.
The aim of this study was to examine the effects of supra-
physiological doses of GCs and vanadate on primary bone-
derived MSCs, with a view of further understanding the etiology 
of GIO and how vanadate ameliorates GC-induced bone disease. 
Bone-derived MSCs can be isolated and cultured from various 
parts of long bones, including bone marrow (14), compact bone 
(15), the periosteal layer (16), or the epiphysis of long bones 
(17). However, many of these studies reported subtle differences 
between bone marrow-derived MSCs (bmMSCs) and MSCs 
derived from other areas of bone, suggesting that not all MSCs 
populations within bone are identical and that these different 
populations may respond differently during disease progression 
and pharmacological treatments (15–17). The typical bmMSC 
isolation procedure utilizes the diaphysis (shaft) of the femur, 
thereby excluding the proximal region of the femur, which is 
particularly susceptible to fracture during GIO compared to 
other bone sites (18, 19). We have therefore isolated MSCs from 
the proximal region of the femur (pfMSCs) and compared these 
cells with bmMSCs in order to investigate whether these two 
osteoprogenitor populations may differ in their responses to GCs 
and vanadate.
MaTerials anD MeThODs
experimental animals
Experiments involving animals were approved by Stellenbosch 
University Ethics Committee and performed in accordance 
with the South African Medical Research Council Guidelines 
on Ethics for Medical Research in compliance with the South 
African Animal Protection Act (Act No. 71 of 1962). Adult 
male Wistar rats [12  weeks old, ~250  g mass, housed at the 
Stellenbosch University Animal Facility and fed ad  libitum on 
standard laboratory chow (Rat and Mouse Breeder Feed, Animal 
Specialities, Pty. Ltd., Klapmuts, South Africa)], were used for all 
experiments. Animals were sacrificed via intraperitoneal injec-
tion with 12 mg kg−1 sodium pentobarbitone (Eutha-naze, Bayer, 
South Africa) and the femora subsequently excised.
cell culture
Isolation of MSCs
Bone marrow-derived MSCs were isolated using a protocol that 
was adapted from Nadri et al. (14) and Zhu et al. (15): The tendon 
and muscle tissue on the femoral surface were manually removed 
with sterile gauze. The ends of the bones were cleaved off at the 
greater trochanter and saved for the isolation of pfMSCs. The 
bone marrow cavity was then flushed with cell isolation media 
[Dulbecco’s Modified Eagle Medium (DMEM) (Lonza, Verviers, 
Belgium)] containing 1% Penicillin/Streptomycin (P/S) (Lonza) 
and 20% fetal bovine serum (FBS) (Biochrom, Berlin, Germany) 
into a 100-mm cell culture dish using a syringe. Bone marrow 
from both femora was pooled and subsequently incubated 
overnight at 37°C in 95% humidified air containing 5% CO2. The 
following day, the culture was washed once with PBS to remove 
any non-adherent cells and debris, and subsequently cultured in 
growth media (DMEM with P/S supplemented with 10% FBS). 
For the isolation of pfMSCs, the protocol was adapted from Zhu 
et al. (15). The proximal region of the femur was macerated into 
1 mm3 fragments and digested at 37°C for 60 min in 10 ml Hanks’ 
Balanced Salt Solution (Lonza) containing 0.075% (w/v) colla-
genase I (#CLS1, Worthington, Lakewood, NJ, USA) and 1.5% 
bovine serum albumin (BSA). The digested proximal femur frag-
ments were then washed five times in DMEM and seeded in a cell 
culture dish with cell isolation media. After 24 h, non-adherent 
material was washed off with PBS and the media replaced with 
standard growth media.
Subculturing and Maintenance
All cell cultures were maintained at 37°C with 5% CO2 and 95% 
humidified air. Once the MSC cultures reached approximately 
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80% confluence, the cells were dissociated using 0.5% trypsin 
solution (Lonza) and sub-cultured at a dilution of 1:4. MSC cul-
tures were expanded to passage 3 before being used for further 
experiments.
MSC Differentiation and Cytological Staining
All constituents of the differentiation media were purchased from 
Sigma-Aldrich (Schnelldorf, Germany). Differentiation experi-
ments were performed in six-well cell culture-treated dishes 
(Porvair, UK). For osteoblastic differentiation, the protocol was 
adapted from Jaiswal et  al. (20). In brief, bmMSCs were cul-
tured to confluence before being treated with osteogenic media 
(OM), which consisted of growth media supplemented with 
50 μM ascorbic acid, 10  mM β-glycerophosphate, and 10  nM 
dexamethasone, with a final ethanol concentration of 0.1%. For 
negative vehicle controls, cells were treated with growth media 
containing 0.1% ethanol. OM was replaced twice a week for 
the duration of osteoblastic differentiation. Once osteoblastic 
differentiation was complete (after day 7 for bmMSCs and day 
21 for pfMSCs), mineralized extracellular deposits were stained 
with Alizarin Red S (Amresco, USA), using a protocol adapted 
from Gregory et al. (21). Briefly, cells were fixed in 70% ethanol 
for 10 min and stained with 40 mM Alizarin Red S dissolved 
in water (pH adjusted to 4.1 with 5% NH4OH). Excess stain 
was removed after 1 h, and the samples were washed twice with 
water. PBS (1 ml) was added to each stained well before image 
capturing using an Olympus CKX41 microscope (CKX41, 
CachN 10×/0.25 PhP objective) and a Canon EOS 600D camera.
For adipocytic differentiation, the protocol was adapted from 
Ogawa et  al. (22). MSCs at passage 3 were cultured to 2  days 
post-confluence before being treated with adipogenic media 
(AM), which consisted of growth media supplemented with 
1 μM dexamethasone, 50 μM ascorbic acid, 56 μM indomethacin, 
10 μM insulin, and 0.5  mM 3-isobutyl-1-methylxanthine. The 
AM was replaced every 2–3 days for the duration of differentia-
tion. For concomitant vanadate treatments, a stock solution of 
10 mM sodium orthovanadate was dissolved in water and boiled 
as per manufacturer’s instructions (Sigma-Aldrich, Schnelldorf, 
Germany), and aliquots were stored at −20°C. Intracellular lipid 
droplets were stained with filtered 0.7% (w/v) Oil Red O (Sigma-
Aldrich) in 70% isopropanol for 30 min and subsequently washed 
three times with water before images were captured as described 
above (23). For quantification of staining, isopropanol was used to 
extract the bound Oil Red O, and the absorbance of the extracted 
dye was measured at 510 nm. To correct for differences in cell 
density, the cells were re-stained with 0.1% (w/v) Crystal Violet 
(CV) nuclear stain, which was extracted with 75% ethanol, and 
the absorbance of the extracted dye was measured at 570 nm. Oil 
Red O absorption values were normalized against corresponding 
crystal violet absorption values (ORO/CV) and expressed as the 
relative triglyceride content.
characterization of Msc Populations 
using Flow cytometry
Bone marrow-derived MSCs and pfMSCs (80% confluent; 
passage 3) were harvested by trypsinisation and re-suspended 
in PBS containing 1% BSA (Sigma-Aldrich, Berlin, Germany). 
Cell suspensions at a concentration of 1 × 106 cells per 100 μl 
were  co-labeled with mouse anti-rat Alexa Fluor 647-conjugated 
CD106 (AbDSerotec #MCA4633A647T), FITC-conjugated 
CD90 (BD Pharmingen, # 554897), V450-conjugated CD45 (BD 
Horizon, # 561587), and PE-conjugated CD26 (BD Pharmingen, 
# 559641). Flow cytometry was performed on a BD FACS Canto 
II instrument using FACSDiva software. A total of 15 000 events 
were recorded prior to data analysis. Since a multicolor cytometric 
analysis was carried out, fluorescent compensation settings were 
established through a compensation experiment, and regions of 
positive and negative staining were determined through a fluo-
rochrome minus one (FMO) experiment. An unstained control 
sample was used as a negative control for gating purposes, and to 
measure forward and side scatter. Data analysis was performed 
using Flow Jo Vx (Treestar, Oregon, USA) software.
cell Viability
Cells at passage 3 were grown to 2 days post-confluence before 
being treated with 1  μM dexamethasone, in the absence or 
presence of 10 μM vanadate, for 7 days. For crystal violet (CV) 
staining, samples were fixed in 70% ethanol, stained with 0.1% 
CV for 5 min, and washed three times with PBS before images 
were captured as described above (see MSC Differentiation and 
Cytological Staining). Crystal violet was then extracted with 
75% ethanol and the absorbance measured at 570  nm. The 
MTT assay protocol was adapted from the MTT-based in vitro 
toxicology assay kit from Sigma-Aldrich. Cells at passage 3 
were seeded into 96-well plates and treatments commenced 
at 2 days post-confluence. Cells were treated for 7 days, after 
which 10 μl of 5 mg/ml MTT stock solution was added to each 
well and incubated for 2 h. The color reaction was stopped by 
the addition of 100 μl of 10% Triton X-100 plus 0.1N HCL in 
isopropanol, and samples were incubated on a plate shaker 
until the color product was completely dissolved. The color 
development was quantified spectrophotometrically at 570 nm, 
and background absorbance at 690  nm was subtracted from 
each well.
apoptosis Detection
For the detection and quantification of apoptosis, pfMSCs were 
expanded to passage 3 and grown to 2  days post-confluence 
before being treated with 1 μM dexamethasone and/or 10 μM 
vanadate for 7  days. Cells were harvested by trypsinization, 
subjected to centrifugation at 400  ×  g for 5  min, and cell 
pellets were re-suspended in PBS. Apoptosis was measured 
according to the PE Annexin V Apoptosis Detection Kit I 
(BD Pharmingen, #559763). Approximately 1 × 106 cells were 
co-stained with PE-conjugated annexin V (a marker of early 
apoptosis) and 7-amino-actinomycin (7-AAD: a marker for the 
loss of membrane integrity and cell death) and incubated in 
the dark at room temperature for 15 min. Flow cytometry was 
performed on the FACSCanto II flow cytometer with FACSDiva 
software, analyzing a total of 10,000 events per sample. Further 
data analysis was performed on Flow Jo Vx (Treestar) software 
where early apoptotic cells were characterized as annexin 
TaBle 1 | Primer sequences used in qrT-Pcr.
gene name 
(symbol)
ref seq no. Primer sequences (5′-3′) Product 
size (bp)
PPARγ2 
(Pparg) (26)
NM_013124.3 F: ACTGCCTATGAGCACTTCAC 448
R: CAATCGGATGGTTCTTCGGA
C/EBPα 
(Cebpa) (26)
NM_012524.3 F: TGGACAAGAACAGCAACGAG 360
R: AATCTCCTAGTCCTGGCTTG
aP2a 
(Fabp4) (27)
NM_053365.1 F: TGAAATCACCCCAGATGACAG 185
R: CTCATGCCCTTTCATAAACT
Adipsinb 
(Cfd)
NM_001077642.1 F: CACGTGTGCGGTGGCACCCTG 475
R: CCCCTGCAAGTGTCCCTGCGGT
ARBP 
(Rplp0) (25)
NM_022402.2 F: AAAGGGTCCTGGCTTTGTCT 91
R: GCAAATGCAGATGGATCG
Fatty acid 
synthasec 
(Fasn)
NM_017332.1 F: GGCCTGGAGTCTATCATCAA 148
R: CTGCACTCAGGGTGTGAT
GLUT4c 
(Slc2a4)
NM_012751.1 F: CTTCCTTCTATTTGCCGTCC 190
R: TGCCCCTCAGTCATTCTCAT
Msx2 (Msx2) 
(28)
NM_012982.3 F: TCACCACGTCCCAGCTTCTAG 178
R: AGCTTTTCCAGTTCCGCCTCC
Runx2/
Cbfa1 
(Runx2) (29)
NM_001278483.1 F: GCGGACGAGGCAAGAGTT 252
R: TTGGTGCTGAGTTCAGGGAG
Wnt10bb 
(Wnt10b)
NM_001108111.1 F: TTCCAGCCCCGCCTACGTCCG 227
R: CAGTGGAAACGACAGTGGC
aForward primer designed by authors.
bPrimers designed by authors.
cPrimers derived from Qiagen RT2 Adipogenesis PCR array.
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V+/7-AAD−. Gating strategy: Unstained cells were used as a 
negative control, whereas cells treated with 50 μg/ml cyclohex-
imide (4, 24, 48 h) to induce apoptosis were used as a positive 
control for Annexin V staining (data not shown). The positive 
control for the nuclear stain, 7-AAD, was obtained through 
prolonged exposure of cells to trypsin in order to permeabilize 
the cell membrane and allow 7-AAD to penetrate the cells 
(data not shown).
gene expression analysis (qrT-Pcr)
For all gene expression analyses, cells were plated into six-well 
plates at passage 3. Cells were prepared for RNA extraction by 
lysis in Qiagen (Berlin, Germany) buffer RLT and then stored at 
−80°C until required. Total RNA was purified using the Qiagen 
RNeasy Mini kit (#74106), and 1 μg total RNA was treated with 
1  U of Promega (Madison, Wisconsin, USA) RQ1 RNase-free 
DNase, as per manufacturer’s instructions. The DNase-treated 
RNA samples were used as a template for cDNA synthesis, 
using 20-(dT) as a primer with Promega ImProm-II reverse 
transcriptase. Real-time semi-quantitative RT-PCR (qRT-PCR) 
was performed on a Rotor-Gene 6000 (Corbett Life Science) 
using the Quantace Sensimix No-ROX kit (Bioline, London, 
England). Sequences for gene-specific primers can be found in 
Table 1. Relative gene expression levels were calculated according 
to the ΔCt method (24) and normalized to the expression of the 
housekeeping gene ARBP (25).
statistical analysis
All statistical analyses were performed with GraphPad Prism 
version 5.01. All data were expressed as average ± SD, and were 
analyzed using one-way ANOVA and Bonferroni’s multiple 
comparison test.
resUlTs
characterization of isolated 
Msc Populations
The cell populations isolated from bone marrow and the 
proximal femur were analyzed at passage 3 using flow cytometry 
in order to assess the homogeneity of the populations as well 
as the expression of cell surface markers associated with the 
MSC phenotype. Both bone marrow-derived and proximal 
femur-derived cell cultures constituted single homogeneous 
populations (Figure  1A), and both cell-types expressed the 
MSC cell surface markers CD90 (bmMSCs 90 ± 2.5%; pfMSCs 
61 ± 9%) and CD106 (bmMSCs 72 ± 4%; pfMSCs 80 ± 5%), but 
not the hematopoietic marker CD45 (bmMSCs 8 ± 3%; pfMSCs 
12 ± 2%) (Figure 1B). Despite biological variability, the overall 
expression of the fibroblast marker, CD26, was slightly higher 
in pfMSCs (53 ±  14%) (n =  8) than in bmMSCs (37 ±  11%) 
(n = 9) (Figure 1B).
comparison of Differentiation Potential 
between pfMscs and bmMscs
Bone marrow-derived MSCs and pfMSCs were treated with OM 
and AM to assess the osteoblastic and adipocytic differentiation 
potential of the cells. BmMSCs rapidly responded to OM treat-
ment and had completely and uniformly mineralized the extra-
cellular matrix within 7 days, while pfMSCs formed individual 
mineralized nodules after 21 days of OM treatment (Figure 2). 
In contrast, pfMSCs exhibited a strong adipogenic response, 
with large numbers of lipid-filled cells apparent by day 7, while 
bmMSCs required 21 days to form intracellular lipid droplets in 
a few individual cells (Figure 3).
The effect of Vanadate on adipogenesis 
in Bone-Derived Mscs
Cytological Staining
In order to determine whether vanadate had an effect on adi-
pogenesis in bone-derived MSCs, pfMSCs and bmMSCs were 
treated with AM in the absence or presence of 10 μM vanadate 
(treatment group AMV). Oil Red O staining was significantly 
decreased by approximately 50% in AMV-treated pfMSCs and 
bmMSCs, compared to AM-treated cells (Figure 4).
Gene Expression Analysis
We hypothesized that the observed partial inhibition of 
AM-stimulated lipid accumulation may be either due to an effect 
on one or more molecules in lipid sequestering or synthesizing 
pathways, or by globally affecting the process of adipogenesis. 
To ascertain whether vanadate inhibits adipogenesis, and to gain 
further insight into the possible mechanism(s) involved, the effect 
FigUre 1 | characterization of bone cell isolates. (a) A scatter plot showing homogeneous populations of bone marrow- and proximal femur-derived cells. (B) 
Cell surface expression of the mesenchymal progenitor cell marker CD90 (column I), bmMSC marker CD106 (column II), fibroblast marker CD26 (column III), and the 
hematopoietic marker CD45 (column IV) was examined using flow cytometry. The first row (1) represents the negative (unstained) control samples, whereas the 
results for surface marker expression in bmMSCs and pfMSCs are shown in rows 2 and 3, respectively. Regions of positive staining are indicated to the right-hand 
side of the vertical line. Experiments were repeated in duplicate on MSCs derived from nine animals (n = 9), and the graphs show the results for one representative 
animal. For each experiment 15,000 events were recorded of which 10,000 were gated and analyzed using FlowJo Vx (Treestar) software.
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of vanadate on the expression of several adipogenesis-related 
genes was examined using qRT-PCR.
The expression of the pivotal activator of adipogenesis, 
PPARγ2, could not be consistently observed in untreated, Naïve 
pfMSCs, and was completely undetectable in Naïve bmMSCs. 
However, PPARγ2 expression was induced in pfMSCs after 
3  days of AM treatment and was maintained until day 7 (the 
last time-point examined for pfMSCs) (Figure 5A). Vanadate did 
not affect the initial upregulation of PPARγ2 expression by day 3, 
but reduced AM-induced PPARγ2 expression by approximately 
70% by day 7 (Figure 5A). In contrast to the rapid upregulation 
of PPARγ2 in pfMSCs, PPARγ2 expression was only induced 
in bmMSCs between 14 and 21 days of AM treatment, and this 
induction was reduced by 30–60% by vanadate (Figure 5A). C/
EBPα expression was readily detectable in untreated pfMSCs and 
bmMSCs (Ct values between 25 and 29), and was upregulated in 
response to AM at all time-points tested (Figure 5B), although 
the magnitude of the response to AM varied between cell isolates. 
In pfMSCs, C/EBPα expression exhibited a stronger induction 
at day 7 of AM treatment than at day 3, and a significant down-
regulation with vanadate at day 7 but not at day 3 (Figure 5B), 
similar to that observed for PPARγ2 (Figure 5A). In bmMSCs, 
vanadate also had very little effect on AM-induced C/EBPα 
expression at earlier time-points (days 7 and 14), but caused a 
60–70% reduction in AM-induced C/EBPα expression by day 21 
(Figure 5B). The late adipogenic markers, aP2/FABP4 (adipocyte 
protein-2, also known as fatty acid binding protein-4), fatty 
acid synthase (Fasn) and adipsin, were strongly upregulated in 
response to AM at day 7 in pfMSCs and day 21 in bmMSCs, 
although the magnitude of the responses varied dramatically. 
As was found for the early adipogenic markers examined, vana-
date caused a significant decrease in the AM-induced expression 
of late adipogenic markers in both cell-types (Figure 6).
inherent Differences in gene expression 
Underlying the Variation in Differentiation 
Potential between pfMscs and bmMscs
Given the similarities in the AM-mediated upregulation of 
adipocyte gene expression in pfMSCs and bmMSCs, and our 
observations that vanadate had similar inhibitory effects on lipid 
accumulation and adipogenic gene expression in both cell types, 
we concluded that it was likely that the mechanisms governing 
adipogenesis and lipid accumulation were largely the same 
in both cell types, even though adipogenesis proceeded more 
rapidly in pfMSCs than in bmMSCs. However, we questioned 
whether differential expression of specific genes before the initia-
tion of adipogenesis could account for the increased rate of lipid 
FigUre 2 | characterization of the osteoblastic differentiation 
potential of bmMscs and pfMscs. Cells were treated with osteogenic 
media (OM) as described under Section “Materials and Methods,” for the 
number of days as indicated on the figure, and subsequently stained with 
Alizarin Red S. Images show representative results of three independent 
experiments, and were taken at 10× magnification, with the size bar = 1 mm.
FigUre 3 | characterization of the adipocytic differentiation potential 
of bmMscs and pfMscs. Cells were treated with adipogenic media (AM) 
as described under Section “Materials and Methods,” for the number of days 
as indicated on the figure, and subsequently stained with Oil Red O. Images 
show representative results of three independent experiments, and were 
taken at 20× magnification, with the size bar = 1 mm.
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accumulation in pfMSCs, compared to bmMSCs. First, we com-
pared the expression of adipocyte-specific genes between Naïve 
pfMSCs and bmMSCs using qRT-PCR. Although the expression 
of C/EBPα and fatty acid synthase was readily detectable in 
both cell types, neither was found to be differentially regulated 
(Figure 7A). Furthermore, the expression levels of aP2/FABP4 in 
Naïve cells varied considerably, but did not correlate with adipo-
genic potential (Figure 7A), and GLUT4 expression was found 
to be very low in both cell types (data not shown). It therefore 
appeared unlikely that the increased lipid accumulation rate of 
pfMSCs could be attributed to elevated adipocyte-specific gene 
expression in the Naïve state, and consequently the expression 
of anti-adipogenic genes was examined. The anti-adipogenic/
pro-osteogenic factors Wnt1, Wnt3a, and sonic hedgehog (Shh) 
(30) were undetectable by qRT-PCR in either cell type (data 
not shown). Expression levels of the pro-osteogenic transcrip-
tion factors Runx2 and Msx2 also did not differ between Naïve 
pfMSCs and bmMSCs (Figure  7B), although the anti-
adipogenic/pro-osteogenic factor Wnt10b (31) was expressed 
in Naïve bmMSCs, but not pfMSCs (Figure 7B). Subsequently 
it was found that Wnt10b expression in AM-treated bmMSCs 
was downregulated after 14 days (Figure 7C), therefore preced-
ing the induction of PPARγ2 expression. Wnt10b expression 
remained downregulated in AM-treated bmMSCs by day 21, but 
was unexpectedly also found to be downregulated by vanadate 
treatment (Figure 7C).
The effects of gcs on lipid accumulation 
and Viability of pfMscs and bmMscs
Given that GC-induced osteoporosis is often associated with 
increased bone marrow adiposity (8), it was questioned whether 
GCs could directly induce adipogenesis in bone-derived MSCs. 
PfMSCs and bmMSCs were treated with 1 μM dexamethasone 
(Dex) for 21  days, but no lipid accumulation was observed 
(Figure  8). It was also hypothesized that GCs may reduce the 
viability of bone-derived MSCs, as it had been previously shown 
that glucocorticoids induced apoptosis in bone cells in vivo and 
in vitro (10). In-well staining of bone-derived MSCs with crystal 
violet or MTT demonstrated a significant decrease in cell density 
of pfMSC cultures that had been treated with 1 μM Dex for 7 days 
(Figures 9A,B). In addition, results from the annexin V apoptosis 
assay indicated an increase in the percentage of apoptotic cells 
in Dex-treated pfMSC cultures (Figure  9C). As previous work 
had found that vanadate could be protective against GC-induced 
apoptosis in an immortalized bone cell line (10), we examined 
FigUre 4 | The effect of vanadate on lipid accumulation in bmMscs and pfMscs. Cells were treated with adipogenic media (AM) or AM plus 10 μM 
vanadate (AMV) for the number of days as indicated, before being stained with Oil Red O (ORO) and counterstained with crystal violet (CV). The ORO/CV ratio for 
control cells was set as 1. Different lower-case letters (a vs. b) indicates statistically significant differences (P < 0.05, with n = 4 for bmMSCs and n = 3 for pfMSCs).
FigUre 5 | The effect of vanadate on the expression of early markers of adipogenesis. (a,B) Cells were treated with adipogenic media (AM) or AM plus 
10 μM vanadate (AMV) for the number of days as indicated, and the expression of PPARγ2 (a) and C/EBPα (B) were measured by qRT-PCR. All target gene 
measurements were normalized to the housekeeping gene acidic ribosomal phosphoprotein (ARBP). (a) As PPARγ2 expression was undetectable in Naïve cells, 
PPARγ2 expression in day 3 AM-treated pfMSCs or day 21 AM-treated bmMSCs was set as 1. The graph presents the combined data of n = 3 for bmMSCs and 
n = 3 for pfMSCs. (B) C/EBPα expression in control cells was set as 1. The graph presents representative data from one experimental repeat out of three repeats 
for bmMSCs and one out of four repeats for pfMSCs.
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whether vanadate could counteract the apoptotic effects of Dex 
on pfMSCs. However, both cytological staining and apoptosis 
measurements showed that vanadate could not rescue pfMSCs 
from the negative effects of Dex treatment (Figures  9A–C). 
Vanadate treatment also had no effect on the viability of bmMSCs 
(Figures 9A,B).
FigUre 6 | The effect of vanadate on the expression of late markers 
of adipogenesis. Cells were treated with adipogenic media (AM) or AM plus 
10 μM vanadate (AMV) for the number of days as indicated, and the 
expression of adipocyte protein-2/fatty acid binding protein-4 (aP2/FABP4), 
adipsin, and fatty acid synthase (Fasn) was measured with qRT-PCR. All 
target gene measurements were normalized to the housekeeping gene acidic 
ribosomal phosphoprotein (ARBP). The expression of aP2/FABP4, adipsin, 
and Fasn in AM-treated cells was set as 1. The graph presents the combined 
data of n = 3 for bmMSCs and n = 4 for pfMSCs. Statistically significant 
differences are indicated as **P < 0.01 or ***P < 0.001.
FigUre 7 | comparison of gene expression between bmMscs and 
pfMscs. The relative expression levels of adipogenic genes (a) and osteogenic 
genes (B) in Naïve bmMSCs and pfMSCs were measured by qRT-PCR. All 
target gene measurements were normalized to the housekeeping gene acidic 
ribosomal phosphoprotein (ARBP). For each target gene, the average 
expression in bmMSCs (n = 3) was set as 1, and the expression in pfMSCs 
(n = 4) calculated relative to expression in bmMSCs. (c) bmMSCs were treated 
with adipogenic media (AM) or AM plus 10 μM vanadate (AMV) as indicated, 
and the expression of Wnt10b was measured by qRT-PCR after 14 and 
21 days. Expression in control cells was set as 1. Different lower-case letters (a 
vs. b vs. c) indicates statistically significant differences (P < 0.05, n = 3).
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DiscUssiOn
In the present study, we report for the first time the isolation and 
characterization of an MSC population, residing in the proximal 
end of rat femurs (pfMSCs) that is phenotypically similar to, but 
functionally distinct from bmMSCs. Compared to bmMSCs, 
pfMSCs exhibited a more rapid adipogenic response but a 
delayed and impaired osteogenic response. However, despite 
these apparent differences in differentiation responses, gene 
expression analysis indicated that the mechanisms involved in 
adipogenesis and lipid accumulation are likely to be the same 
in both cell types. It was also found that GCs strongly reduced 
the viability of pfMSCs by stimulating apoptosis in these cells, 
while bmMSCs were resistant to the cytotoxic effects of GCs. 
Vanadate partially inhibited adipogenesis and lipid accumula-
tion in both cell types, but could not reverse the GC-induced 
cytotoxicity in pfMSCs.
Cell surface marker analysis indicated that both pfMSCs and 
bmMSCs were strongly positive for the mesenchymal markers 
CD90 (32) and CD106 (33), and negative for the hematopoi-
etic marker CD45 (34). However, it was found that CD26 was 
expressed at higher levels in pfMSCs than in bmMSCs. CD26 
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is considered to be a fibroblast marker, and earlier work has 
described that CD26 and CD106 may be used to distinguish 
between bmMSCs and fibroblasts (33, 35). However, fibroblasts 
are terminally differentiated cells, whereas the maintenance of 
an undifferentiated phenotype, proliferative- and bipotential 
differentiation capacity shown in the bmMSCS and pfMSCs in 
the present study indicate that these are Naïve progenitor cells, 
suggesting that CD26 expression is not absolutely indicative of 
the differentiated fibroblastic phenotype.
The most dramatic difference observed between pfMSCs and 
bmMSCs was in the adipocytic and osteoblastic differentiation 
potential, with pfMSCs being highly adipogenic and bmMSCs 
being highly osteogenic. Unexpectedly, despite these differences 
in differentiation potential, neither cell types exhibited spontane-
ous differentiation in culture, and we found that the expression 
of pro-adipogenic (PPARγ2, C/EBPα) (36) and pro-osteogenic 
transcription factors (Runx2, Msx2) (37, 38), as well as factors 
related to adipocyte function (aP2/FABP4, fatty acid synthase, 
GLUT4) (39, 40), did not differ between Naïve pfMSCs and 
bmMSCs. However, we found that Wnt10b was expressed in 
bmMSCs, but was absent in pfMSCs.
It is well established that an inverse relationship exists 
between osteoblastogenesis and adipogenesis in MSCs, with 
signals stimulating the one process often reciprocally inhibiting 
the other (5, 41). Wnt10b was first identified as a crucial “off-
switch” for adipogenesis in vitro in 3T3-L1 pre-adipocytes (42) 
and subsequently in  vivo in transgenic mice (43). Conversely, 
it was found that Wnt10b promoted osteoblastogenesis in vitro 
in bipotential ST2 cells (31, 44) and in vivo in transgenic mice 
(44, 45). Furthermore, proximal femur bone samples from 
osteoporotic women with hip fractures exhibit decreased 
Wnt10b expression (46), providing evidence for a relationship 
between Wnt10b expression, the maintenance of osteoblastic 
differentiation and bone strength. In addition, calvarial cultures 
from transgenic mice with reduced Wnt10b expression displayed 
dominant adipogenesis and a reduction in osteoblastogenesis 
(47), similar to the association between Wnt10b expression and 
osteoblastic differentiation seen in pfMSCs and bmMSCs in the 
present study. It may therefore be likely that the difference in 
differentiation potential between pfMSCs and bmMSCs is driven, 
at least in part, by a dissimilarity in Wnt10b expression. However, 
apart from Wnt10b expression and the concomitant delay in the 
onset of adipogenesis in bmMSCs, compared to pfMSCs, the 
profile of adipogenesis-related genes expressed in response to 
AM did not differ between these two cell types, indicating that 
the mechanism of adipocyte development from these two distinct 
progenitor populations was highly similar.
Glucocorticoid-induced osteoporosis is often associated with 
a decrease in osteoblast number and an increase in bone mar-
row adiposity (8). Previously, it has been found that vanadate 
prevented GC-induced osteoporosis in vivo in rats by restoring 
osteoblast numbers and preventing osteocyte apoptosis (10, 12). 
However, to our knowledge, there is no information available on 
the effects of vanadate on adipogenesis and lipid accumulation 
in bone-derived MSCs. The results presented here indicate that 
vanadate was able to inhibit lipid accumulation and the expression 
of early and late adipogenesis markers in pfMSCs and bmMSCs, 
demonstrating that vanadate inhibited the adipogenic program, 
and not just the later phases of lipid accumulation, similar to 
that previously found in immortalized 3T3-L1 pre-adipocytes 
(13). However, it should be noted that AM-induced expression 
of the early adipogenesis markers PPARγ2 and C/EBPα was only 
inhibited by vanadate at later time-points, after the expression of 
these genes had been upregulated by AM, suggesting the possibil-
ity that vanadate-mediated inhibition of adipogenesis involves an 
upstream signal that is induced during the initial phases of the 
FigUre 8 | The effect of gc treatment on bmMscs and pfMscs. BmMSCs and pfMSCs were treated with 1 μM dexamethasone (Dex) for 21 days, and 
compared to vehicle-treated cells. Images show unstained cells at 20× magnification and are representative of three independent experiments. The size bar = 1 mm.
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FigUre 9 | The effects of gcs and vanadate on cell viability and 
apoptosis in bmMscs and pfMscs. Naïve cells were treated with 1 μM 
dexamethasone (Dex) in the absence or presence of 10 μM vanadate. (a,B) 
Cells were stained with crystal violet (a) or MTT (B), and the staining was 
quantified spectrophotometrically. Absorbance measurements of control cells 
were set as 1. (c) The percentage of apoptotic cells in treated pfMSC 
cultures was determined with flow cytometry, using annexin V as an apoptotic 
marker. Statistically significant differences are indicated as *P < 0.05, 
**P < 0.01, or ***P < 0.001 (n = 3 for bmMSCs, n = 3 for pfMSCs).
adipogenic response, with consequential effects only occurring 
later in the differentiation process. Furthermore, we observed that 
the vanadate-mediated inhibition of adipogenesis in bmMSCs 
was not associated with upregulated expression of the anti-
adipogenic Wnt10b (42, 43), but that Wnt10b was unexpectedly 
downregulated by AM as well as by vanadate. The inhibition of 
adipogenesis in MSCs by vanadate is therefore not underpinned 
by increased Wnt10b expression, suggesting that other signals 
are activated by vanadate that can inhibit adipogenesis without a 
requirement for Wnt10b.
Our finding that bmMSCs showed no differences in cell 
viability when cultured in a high concentration of Dex (1 μM) 
suggests that cultured primary bmMSCs are resistant to the det-
rimental effects of high doses of GCs, even though other studies 
have described decreased viability, proliferation and osteogenic 
potential in bmMSCs isolated from GC-treated animals (7, 48). It 
is therefore possible that these effects of GCs are not the result of 
direct GC actions at a cellular level, but that they may be mediated 
systemically. In contrast, pfMSCs were found to be exquisitely 
sensitive to the cytotoxic and apoptotic effects of GCs, but these 
effects could not be counteracted by vanadate co-administration. 
This is in contrast with previous findings, which demonstrated 
that in  vivo vanadate treatment could rescue osteoblasts and 
osteocytes from the negative effects of GCs (10, 12), again sug-
gesting that the effects of GCs and vanadate on bone may be 
systemic rather than direct.
It has been noted that GC-induced osteoporosis may result in a 
greater increase in fractures of the vertebrae and proximal femur, 
compared to fractures at other sites (18, 19), and that GC-induced 
fat conversion takes place in the proximal femur (8). In addition, 
studies on patients with GC-induced osteonecrosis of the proxi-
mal femur found a decreased proliferative capacity in isolated 
MSCs (49) and a decrease in progenitor cell numbers in regions 
adjacent to the necrotic areas (50). Moreover, it was demonstrated 
in rabbit models that GC treatment induced both marrow fat cell 
hyperplasia and hypertrophy in the proximal femur (51, 52), and 
that GC-induced osteonecrosis was also associated with marrow 
fat cell hypertrophy in this region of bone (53). While our results 
indicated that GCs alone could not induce lipid accumulation in 
either pfMSCs or bmMSCs, GC treatment reduced the viability 
and increased apoptosis in pfMSCs, but not in bmMSCs. These 
findings, taken together with the highly adipogenic nature of 
pfMSCs, compared to bmMSCs, suggest that distinct MSC popu-
lations may exist in the proximal femur that are more susceptible 
to adipogenic and apoptotic signals than other bone-derived MSC 
populations, such as bmMSCs. In addition, it may also be possible 
that the fat content of the proximal femur, which is usually labeled 
as “marrow adiposity,” may actually arise from distinct pfMSCs, 
rather than from bmMSCs from the diaphyseal region.
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